ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.163,52
-0,41%
S&P 500
5.464,62
-0,16%
Dow Jones
39.150,33
0,04%
Euro vs US Dollar
1,06925
0,00%
Bitcoin
64.368,19
0,19%
Registration Strip Icon for alerts Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Geron Corp (GERN)

  7. Geron Corp (GERN) News

GERN

Geron (GERN)

Geron Corp
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:GERN
DatumZeitQuelleÜberschriftSymbolFirma
20/06/202422h30Business WireGeron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:GERNGeron Corp
12/06/202422h05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GERNGeron Corp
12/06/202422h05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GERNGeron Corp
10/06/202423h53Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:GERNGeron Corp
10/06/202418h30Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:GERNGeron Corp
07/06/202422h10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GERNGeron Corp
07/06/202422h10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GERNGeron Corp
07/06/202422h10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GERNGeron Corp
07/06/202422h10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GERNGeron Corp
07/06/202422h10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GERNGeron Corp
07/06/202422h10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GERNGeron Corp
07/06/202422h03Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:GERNGeron Corp
07/06/202403h58Business WireGeron Announces FDA Approval of RYTELO™ (imetelstat), a First-in-Class Telomerase Inhibitor, for the Treatment of Adult Patients with Lower-Risk MDS with Transfusion-Dependent AnemiaNASDAQ:GERNGeron Corp
05/06/202422h05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GERNGeron Corp
04/06/202423h02Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:GERNGeron Corp
17/05/202422h05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GERNGeron Corp
16/05/202422h30Business WireGeron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:GERNGeron Corp
15/05/202422h07Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:GERNGeron Corp
13/05/202422h05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:GERNGeron Corp
02/05/202413h00Business WireGeron Corporation Reports First Quarter 2024 Financial Results and Business HighlightsNASDAQ:GERNGeron Corp
25/04/202422h30Business WireGeron to Announce First Quarter 2024 Financial Results on May 2, 2024NASDAQ:GERNGeron Corp
18/04/202422h30Business WireGeron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:GERNGeron Corp
03/04/202422h30Business WireGeron to Participate at Upcoming Investor Conferences in AprilNASDAQ:GERNGeron Corp
19/03/202414h07Business WireGeron Corporation Announces Pricing of $150 Million Underwritten Offering of Common Stock and Pre-Funded WarrantsNASDAQ:GERNGeron Corp
14/03/202420h54Business WireGeron Announces FDA Oncologic Drugs Advisory Committee Votes in Favor of the Clinical Benefit/Risk Profile of Imetelstat for the Treatment of Transfusion-Dependent Anemia in Patients with Lower-Risk MDSNASDAQ:GERNGeron Corp
28/02/202413h20Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:GERNGeron Corp
28/02/202413h05Business WireGeron Corporation Reports Business Highlights and Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:GERNGeron Corp
22/02/202422h30Business WireGeron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:GERNGeron Corp
16/02/202422h11Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GERNGeron Corp
16/02/202422h10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GERNGeron Corp
 Showing the most relevant articles for your search:NASDAQ:GERN

Kürzlich von Ihnen besucht

BIT
1BNP
BNP Paribas
UNSW3
LEASHUSDT
DOGE KILLER
UNSW3
TXLETH
Tixl Token
COIN
MAPSUSD
Maps.me Token
TSXV
TTT
NASDAQ
SKYY
First Trust Cloud Comput...
NASDAQ
TRJMX
T Rowe Price Retirement ...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten